company logo

Director, Securities Counsel at Editas Medicine in Cambridge, MA



$200K — $250K *


Legal & Regulatory


11 - 15 years

Job Description

See More

Valid through: 8/18/2020

About Editas Medicine

Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. The company went public on 2 Feb 2016. This initial public offering was noted as being the first such from a company which aims to use "DNA itself to internally treat afflictions". The company has conceded that “It will be many years, if ever, before we have a product candidate ready for commercialization.” Further, the companys valuation depends on a single patent, which holder was in dispute as of early 2016, presenting a major risk to the companys continued viability. The company entered into a strategic collaboration with Juno Therapeutics in 2015 to combine its CRISPR-Cas9 technology with Junos experience in creating chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. The company announced in 2015 that it was planning a clinical trial in 2017 using CRISPR gene editing techniques to treat Lebers congenital amaurosis, a rare genetic illness that causes blindness.
Total Jobs:
Total Experts:
Average Pay:
Total value of jobs:
% Masters:
Learn More About Editas Medicine
* Ladders Estimates